Maltodextrin
CAS 9050-36-6
Maltodextrin (CAS 9050-36-6) is a pharmaceutical compound with 0 bioactivity targets and 29 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Maltodextrin is linked to DTXSID5027720 in DSSTox identifiers.
View industrial chemical data →Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| MALTODEXTRIN | 1363050 | SU | MTHSPL |
| Maltodextrin | 1363050 | SU | MTHSPL |
| maltodextrin | 1363050 | SU | MTHSPL |
| maltodextrin | 1363050 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Maltodextrin used for in pharmaceutical contexts?
Maltodextrin (CAS 9050-36-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Maltodextrin?
Maltodextrin has 29 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abdominal distension, Condition aggravated, Disseminated intravascular coagulation, Gastrointestinal haemorrhage, Laryngitis fungal. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Maltodextrin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Maltodextrin with EU status "permitted".
What clinical phase is Maltodextrin in?
No phase 1-4 clinical development badge is rendered for Maltodextrin because the matched compound identifier rows do not contain a max-phase value.